In Slico Screening and In Vitro Identification of Hyperuricemia-Inhibiting Peptides from

Zexuan Xu, Miaoyu Gan, Weiliang Guan, Fang Tian, Yuxi Wang, Jinjie Zhang, Luyun Cai

Abstract read

In one paragraph

Article in Foods (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zexuan XuCollege of Food and Pharmaceutical Sciences, Ningbo University, Ningbo 315211, China.

Miaoyu GanNingbo Innovation Center, College of Biosystems and Food Science, Zhejiang University, Ningbo 315100, China.

Weiliang GuanSchool of Light Industry and Food Engineering, Guangxi University, Nanning 530004, China.ORCID 0009-0008-1235-817X

Fang TianKey Laboratory of Health Risk Factors for Seafood of Zhejiang Province, School of Food and Pharmacy, Zhejiang Ocean University, Zhoushan 316022, China.ORCID 0000-0002-0429-2851

Yuxi WangNingbo Innovation Center, College of Biosystems and Food Science, Zhejiang University, Ningbo 315100, China.

Jinjie ZhangCollege of Food and Pharmaceutical Sciences, Ningbo University, Ningbo 315211, China.

Luyun CaiNingbo Innovation Center, College of Biosystems and Food Science, Zhejiang University, Ningbo 315100, China.ORCID 0000-0003-3996-1565

Funding

Key R&D Program of Ningbo 2024Z277Ningbo Public Welfare Key Project 2022S148Ningbo Team Science and Technology Commissioner Project 2023S235

6 · The paper itself

Abstract

Hyperuricemia arises from imbalanced uric acid metabolism, contributing to gout and related chronic diseases. When traditional drugs are used to treat hyperuricemia, side effects are inevitable, which promotes the exploration of new bioactive compounds. Protein hydrolysates and peptides are gradually showing potential in the treatment of hyperuricemia. This study investigated the uric acid inhibitory activity of peptides extracted from

Indexed as

hyperuricemiamolecular dockingmolecular dynamicspeptidesuric acid

Identifiers

PMID39942117

DOI10.3390/foods14030524

PMCPMC11817512

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.